Unichem Laboratories gets USFDA nod for Metronidazole tablets

Unichem Laboratories has received approval from the US Food & Drug Administration to sell

RELATED ARTICLES

generic Metronidazole tablets, an anti-infective agent, in the American market.

The approval is for Metronidazole in strengths of 250 mg and 500 mg, which are therapeutically equivalent to Flagyl Tablets of corresponding strengths of GD Searle LLC, the company said in a filing to the BSE.

The drug is an anti-infective agent used to treat a variety of bacterial and protozoal infections.

The product will be commercialised from Unichem's Ghaziabad plant. Active pharmaceutical ingredient Metronidazole used for this ANDA is also made in-house at Roha plant, it said.

At present, around six other companies have generic approvals for the US market and the estimated market size is over $100 million, the company added.

Shares of Unichem Laboratories were trading at Rs 216 per scrip in the afternoon trade, up 0.87 per cent from the previous close, on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Sebi’s proposal to bring clarity to merger moves is a welcome step

    Market regulator Sebi is reportedly planning changes in rules governing merger and acquisition of companies in India.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Kumar Jain

Prosperity mantra across the ages

The economic prosperity of a nation rests upon its ability ...

Kuruvilla Pandikattu SJ

Can we pop a pill for compassion?

Can altering brain chemistry make us more sensitive to inequality? ...

Gautam Gupta

Fashion forward for e-commerce industry?

Looks like the e-commerce industry is taking a leaf out ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture